Success Metrics

Active Trials
1(25%)

Phase Distribution

Ph phase_1
1
25%
Ph phase_2
1
25%
Ph phase_4
2
50%

Phase Distribution

1

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 4Post-market surveillance
2(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Other(3)

Detailed Status

unknown3
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
N/A
Most Advanced
Phase 4

Trials by Phase

Phase 11 (25.0%)
Phase 21 (25.0%)
Phase 42 (50.0%)

Trials by Status

recruiting125%
unknown375%

Recent Activity

1 active trials
Showing 4 of 4
recruitingphase_1

Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC

NCT05842317
unknownphase_4

Lenvatinib Plus TACE Versus Sorafenib Plus TACE for HCC With PVTT

NCT04127396
unknownphase_2

Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE

NCT03642561
unknownphase_4

Clinical Trial of Cinobufacini Combined With Transarterial Chemoembolization (TACE) on Primary Liver Cancer

NCT03843229

Clinical Trials (4)

Showing 4 of 4 trials
NCT05842317Phase 1

Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC

Recruiting
NCT04127396Phase 4

Lenvatinib Plus TACE Versus Sorafenib Plus TACE for HCC With PVTT

Unknown
NCT03642561Phase 2

Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE

Unknown
NCT03843229Phase 4

Clinical Trial of Cinobufacini Combined With Transarterial Chemoembolization (TACE) on Primary Liver Cancer

Unknown

All 4 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
4